MedTrace Logo

Development of an Artificial Intelligence Model for Optimising Therapy in Gliomas Gliomas

NCT06620055 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 164

Last updated 2024-10-01

No results posted yet for this study

Summary

Artificial intelligence (AI) undoubtedly represents the main tool currently available in the definition of complex algorithms and its use in the medical field is becoming increasingly strategic.As reported in the literature, it is increasingly difficult to find new therapeutic strategies for neoplasms, especially neurological ones. Molecular characterisation is therefore increasingly essential, as is the use of new predictive methods.

With this in mind, the aim of this study is to assess, by means of AI algorithms applied to genomic data, in what percentage molecular alterations are susceptible to potential drug therapies, compared to the literature data that does not consider AI algorithms for this purpose.

Conditions

Sponsors & Collaborators

  • Centro di Riferimento Oncologico - Aviano

    lead OTHER

Principal Investigators

  • Giuseppe Toffoli · Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS

  • Maurizio Polano · Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-16
Primary Completion
2028-11-16
Completion
2028-11-16

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06620055 on ClinicalTrials.gov